Detection of transfused platelets in a patient with Glanzmann thrombasthenia

Thrombosis and Haemostasis

Volumn 87, Issue 3, 2002, Pages 543-544

  Nurden, Alan ^a   Combrié, Robert ^a   Nurden, Paquita ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; MONOCLONAL ANTIBODY; FIBRINOGEN RECEPTOR;

AGED; BLEEDING; BLOOD DONOR; CASE REPORT; CIRCULATION; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENE MUTATION; GLANZMANN DISEASE; HETEROZYGOSITY; HIP DISEASE; HISTOGRAM; HOSPITALIZATION; HUMAN; LETTER; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; TOTAL HIP PROSTHESIS; CHEMISTRY; CYTOLOGY; THROMBOCYTE;

AGED; BLOOD PLATELETS; FLOW CYTOMETRY; HUMANS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; THROMBASTHENIA;

EID: 0036124826     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613041     Document Type: Letter

References (14)

1. Use of recombinant factor VIIa in hereditary bleeding disorders
2. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures
3. The factor VII-platelet interplay: Effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopenia
4. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders
5. The molecular genetics of Glanzmann's thrombasthenia
6. The human platelet membrane glycoprotein complex GPIIb-IIIa expresses antigenic sites not exposed on the dissociated glycoproteins
7. 3 of platelets and endothelial cells
8. Repertoire cloning of a human IgG inhibitor of αIIbβ3 function. The OG idiotype
9. A novel Leu196 to Pro substitution in the β3 subunit of the αIIbβ3 integrin in a patient with a variant form of Glanzmann thrombasthenia
10. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets
11. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb-IIIa
12. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
13. Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes
14. Expression of markers of platelet activation and the interpatient variation in response to abciximab